Sensitive Detection of Cell-Free Tumour DNA Using Optimised Targeted Sequencing Can Predict Prognosis in Gastro-Oesophageal Cancer
Overview
Authors
Affiliations
In this longitudinal study, cell-free tumour DNA (a liquid biopsy) from plasma was explored as a prognostic biomarker for gastro-oesophageal cancer. Both tumour-informed and tumour-agnostic approaches for plasma variant filtering were evaluated in 47 participants. This was possible through sequencing of DNA from tissue biopsies from all participants and cell-free DNA from plasma sampled before and after surgery (n = 42), as well as DNA from white blood cells (n = 21) using a custom gene panel with and without unique molecular identifiers (UMIs). A subset of the plasma samples (n = 12) was also assayed with targeted droplet digital PCR (ddPCR). In 17/31 (55%) diagnostic plasma samples, tissue-verified cancer-associated variants could be detected by the gene panel. In the tumour-agnostic approach, 26 participants (59%) had cancer-associated variants, and UMIs were necessary to filter the true variants from the technical artefacts. Additionally, clonal haematopoietic variants could be excluded using the matched white blood cells or follow-up plasma samples. ddPCR detected its targets in 10/12 (83%) and provided an ultra-sensitive method for follow-up. Detectable cancer-associated variants in plasma correlated to a shorter overall survival and shorter time to progression, with a significant correlation for the tumour-informed approaches. In summary, liquid biopsy gene panel sequencing using a tumour-agnostic approach can be applied to all patients regardless of the presence of a tissue biopsy, although this requires UMIs and the exclusion of clonal haematopoietic variants. However, if sequencing data from tumour biopsies are available, a tumour-informed approach improves the value of cell-free tumour DNA as a negative prognostic biomarker in gastro-oesophageal cancer patients.
Mahmood U, Muhamad Faizul E, Howlett S, Amin Z, Hochhauser D, Shiu K Cancers (Basel). 2024; 16(4).
PMID: 38398088 PMC: 10886944. DOI: 10.3390/cancers16040697.
Zhang Y, Du H, Wang N, Wang L, Huang Y BMC Cancer. 2024; 24(1):129.
PMID: 38267901 PMC: 10809487. DOI: 10.1186/s12885-024-11879-6.
Mu N, Jylha C, Axelsson T, Syden F, Brehmer M, Tham E World J Urol. 2023; 41(12):3421-3427.
PMID: 37721600 PMC: 10693512. DOI: 10.1007/s00345-023-04583-w.
Liquid Biopsy in Gastrointestinal Cancers: How Close Are We to Reaching the Clinic?.
Earl J, Kataki A, Smolkova B Cancers (Basel). 2023; 15(10).
PMID: 37345168 PMC: 10216095. DOI: 10.3390/cancers15102831.
Haider Z, Wasterlid T, Spangberg L, Rabbani L, Jylha C, Thorvaldsdottir B Front Oncol. 2023; 13:1176698.
PMID: 37333831 PMC: 10272573. DOI: 10.3389/fonc.2023.1176698.